Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.61 -18.3%	$1.02	$0.46 ▼ $7.49	$10.53M	-0.17	1.43 million shs	1.32 million shs
BRM BioRem	C$2.22 -2.2%	C$2.14	C$1.67 ▼ C$3.45	C$36.40M	0.85	73,519 shs	43,596 shs
CRDL Cardiol Therapeutics	$1.19	$1.30	$0.77 ▼ $2.63	$98.35M	1.04	310,202 shs	345,885 shs
GXE Gear Energy		C$0.50	C$0.45 ▼ C$0.80	C$126.52M	3.52	585,822 shs	1.03 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	+1.55%	+111.83%	+80.75%	+136.98%	-48.70%
BRM BioRem	+0.44%	0.00%	+6.07%	+15.82%	+11.27%
CRDL Cardiol Therapeutics	-8.46%	-13.14%	-13.14%	+17.82%	-43.60%
GXE Gear Energy	0.00%	0.00%	0.00%	0.00%	-35.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	1.5055 of 5 stars	0.0	5.0	0.0	0.0	2.4	1.7	0.6
BRM BioRem	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	2.4667 of 5 stars	3.7	3.0	0.0	0.0	2.7	0.0	0.6
GXE Gear Energy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
BRM BioRem	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	572.27% Upside
GXE Gear Energy	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRM, CRDL, APM, and GXE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	20.03	N/A	N/A	$2.20 per share	0.73
BRM BioRem	C$41.84M	0.87	C$0.60 per share	3.70	C$0.63 per share	3.52
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
GXE Gear Energy	C$134.93M	0.00	N/A	540.00	C$0.93 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
BRM BioRem	C$5.40M	C$0.32	6.86	∞	N/A	12.91%	65.14%	14.61%	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	8/11/2025 (Estimated)
GXE Gear Energy	C$13.02M	C$0.05	10.39	N/A	N/A	8.53%	5.08%	4.84%	N/A

Latest BRM, CRDL, APM, and GXE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
BRM BioRem	N/A	6.47%	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
GXE Gear Energy	C$0.06	11.46%	N/A	120.00%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
BRM BioRem	37.47	1.91	1.08
CRDL Cardiol Therapeutics	0.01	3.26	3.26
GXE Gear Energy	6.27	1.20	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
BRM BioRem	0.47%
CRDL Cardiol Therapeutics	12.49%
GXE Gear Energy	2.42%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
BRM BioRem	1.90%
CRDL Cardiol Therapeutics	5.25%
GXE Gear Energy	7.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
BRM BioRem	34,300	16.40 million	N/A	Not Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
GXE Gear Energy	1,310	263.58 million	N/A	Not Optionable

BRM, CRDL, APM, and GXE Headlines

Recent News About These Companies

Gear Energy Stock Price Today | TSX: GXE Live - Investing.com

June 27, 2025 | investing.com

Don Gray Acquires 1,953,000 Shares of Gear Energy Ltd. (TSE:GXE) Stock

January 28, 2025 | insidertrades.com

Insider Buying: Gear Energy Ltd. (TSE:GXE) Senior Officer Purchases 157,500 Shares of Stock

December 28, 2024 | insidertrades.com

Insider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 333,000 Shares of Stock

December 25, 2024 | insidertrades.com

Stocks in play: Gear Energy Ltd.

December 3, 2024 | theglobeandmail.com

Gear Energy (GXE) Earnings Dates & Reports

November 6, 2024 | investing.com

Gear Energy: Growth Ahead

October 10, 2024 | seekingalpha.com

Gear Energy Ltd. (TSE:GXE) Director Scott Robinson Purchases 74,000 Shares

October 4, 2024 | insidertrades.com

Don't Buy Gear Energy Ltd. (TSE:GXE) For Its Next Dividend Without Doing These Checks

September 8, 2024 | finance.yahoo.com

Gear Energy Ltd. (TSE:GXE) Senior Officer Sells C$71,000.00 in Stock

July 13, 2024 | insidertrades.com

Insider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 192,900 Shares of Stock

May 10, 2024 | insidertrades.com

Gear Energy Ltd. (TSE:GXE) Director Acquires C$226,765.00 in Stock

May 9, 2024 | insidertrades.com

Gear Energy First Quarter 2024 Earnings: EPS: CA$0.01 (vs CA$0.008 in 1Q 2023)

May 7, 2024 | finance.yahoo.com

Gear Energy Ltd. (TSE:GXE) Director Purchases C$515,015.00 in Stock

May 7, 2024 | insidertrades.com

Here's what Wall Street expects from Gear Energy's earnings report

May 1, 2024 | markets.businessinsider.com

Insider Buying: Gear Energy Ltd. (TSE:GXE) Director Buys 26,000 Shares of Stock

April 13, 2024 | insidertrades.com

It Might Not Be A Great Idea To Buy Gear Energy Ltd. (TSE:GXE) For Its Next Dividend

April 7, 2024 | finance.yahoo.com

Guilty Gear Strive: Every Fighter's Skill Set And Difficulty

March 30, 2024 | msn.com

Gear Energy Ltd. (TSE:GXE) Senior Officer Sells C$18,459.00 in Stock

March 23, 2024 | insidertrades.com

GXE:CA Gear Energy Ltd.

March 22, 2024 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRM, CRDL, APM, and GXE Company Descriptions

Aptorum Group NASDAQ:APM

$1.61 -0.36 (-18.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 -0.05 (-3.11%)

As of 07:59 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

BioRem CVE:BRM

C$2.22 -0.05 (-2.20%)

As of 03:59 PM Eastern

BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.

Cardiol Therapeutics NASDAQ:CRDL

$1.19 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 +0.02 (+1.60%)

As of 07:27 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Gear Energy TSE:GXE

Gear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time